

The Impact of Platelet Transfusion in Massively Transfused Trauma Patients

Kenji Inaba, MD, FACS, Thomas Lustenberger, MD, Peter Rhee, MD, FACS, John B Holcomb, MD, FACS, Lorne H Blackbourne, MD, FACS, Ira Shulman, MD, Janice Nelson, MD, Peep Talving, MD, FACS, Demetrios Demetriades, MD, FACS

-
- BACKGROUND:** The impact of platelet transfusion in trauma patients undergoing a massive transfusion (MT) was evaluated.
- STUDY DESIGN:** The Institutional Trauma Registry and Blood Bank Database at a Level I trauma center was used to identify all patients requiring an MT (≥ 10 packed red blood cells [PRBC] within 24 hours of admission). Mortality was evaluated according to 4 apheresis platelet (aPLT):PRBC ratios: Low ratio ($<1:18$), medium ratio ($\geq 1:18$ and $<1:12$), high ratio ($\geq 1:12$ and $<1:6$), and highest ratio ($\geq 1:6$).
- RESULTS:** Of 32,289 trauma patients, a total of 657 (2.0%) required an MT. At 24 hours, 171 patients (26.0%) received a low ratio, 77 (11.7%) a medium ratio, 249 (37.9%) a high ratio, and 160 (24.4%) the highest ratio of aPLT:PRBC. After correcting for differences between groups, the mortality at 24 hours increased in a stepwise fashion with decreasing aPLT:PRBC ratio. Using the highest ratio group as a reference, the adjusted relative risk of death was 1.67 (adjusted $p = 0.054$) for the high ratio group, 2.28 (adjusted $p = 0.013$) for the medium ratio group, and 5.51 (adjusted $p < 0.001$) for the low ratio group. A similar stepwise increase in mortality with decreasing platelet ratio was observed at 12 hours after admission and for overall survival to discharge. After stepwise logistic regression, a high aPLT:PRBC ratio (adjusted $p < 0.001$) was independently associated with improved survival at 24 hours.
- CONCLUSIONS:** For injured patients requiring a massive transfusion, as the apheresis platelet-to-red cell ratio increased, a stepwise improvement in survival was seen. Prospective evaluation of the role of platelet transfusion in massively transfused patients is warranted. (J Am Coll Surg 2010;211: 573–579. © 2010 by the American College of Surgeons)
-

For the critically ill trauma patient who has sustained massive blood loss, the principles governing the acute resuscitation process have shifted, with an increased emphasis on

aggressive blood component therapy.^{1–5} This has been driven by both military^{6–8} and civilian^{9–17} data, supporting the use of plasma early, in ratios approaching 1:1 for patients requiring a massive transfusion (MT), defined in most research protocols as ≥ 10 units of packed red blood cells (PRBC) within the first 6 to 24 hours after admission.

The role of other blood components, such as platelets, however, is less clear. In theory, aggressive platelet transfusion is not unreasonable because it is a critical component of the functional clotting response to injury. Stored at room temperature and transfused as a type specific product, technically, the logistics of early aggressive platelet transfusion can be supported by most blood banking systems provided sufficient product is available. However, unlike the rapidly expanding evidence base exploring the impact that plasma exerts on mortality, relatively little is available to guide platelet transfusion in the resuscitation of critically ill trauma patients.^{10,13 18–20}

The objective of this study was to determine the impact of an increasing platelet-to-PRBC ratio on the outcomes of

Disclosure Information: Nothing to disclose.

Presented at the 68th Annual Meeting of the American Association for the Surgery of Trauma, Pittsburgh, PA, October 2009.

Received April 24, 2010; Revised June 24, 2010; Accepted June 30, 2010.
From the Division of Trauma, Emergency Surgery and Surgical Critical Care, Los Angeles County and University of Southern California Medical Center, Los Angeles, CA (Inaba, Lustenberger, Talving, Demetriades), the Division of Trauma, Critical Care and Emergency Surgery, University of Arizona, Tucson, AZ (Rhee); the Division of Acute Care Surgery, Center for Translational Injury Research, University of Texas Medical School at Houston, Houston, TX (Holcomb), the United States Army Institute of Surgical Research, Fort Sam Houston, San Antonio, TX (Blackbourne) and the Department of Pathology, University of Southern California Medical Center, Los Angeles, CA (Shulman, Nelson).

Correspondence address: Kenji Inaba, MD, FRCSC, FACS, University of Southern California – Keck School of Medicine, Division of Trauma, Emergency Surgery and Surgical Critical Care, LAC + USC Medical Center, 1200 North State St, IPT, C5L100, Los Angeles, CA, 90033-4525. Email: kinaba@surgery.usc.edu

Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE 01 NOV 2010		2. REPORT TYPE N/A		3. DATES COVERED -	
4. TITLE AND SUBTITLE The impact of platelet transfusion in massively transfused trauma patients				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Inaba K., Lustenberger T., Rhee P., Holcomb J. B., Blackbourne L. H., Shulman I., Nelson J., Talving P., Demetriades D.,				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) United States Army Institute of Sutgical Research, JBSA Fort Sam Houston, TX				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 7	19a. NAME OF RESPONSIBLE PERSON
a REPORT unclassified	b ABSTRACT unclassified	c THIS PAGE unclassified			

Abbreviations and Acronyms

adj	= adjusted
AIS	= Abbreviated Injury Score
aPLT	= apheresis platelet
GCS	= Glasgow Coma Scale
ISS	= Injury Severity Score
MT	= massive transfusion
OR	= odds ratio
PRBC	= packed red blood cells

trauma patients who required a massive transfusion. Our hypothesis was that aggressive platelet transfusion improves survival.

METHODS

The Los Angeles County + University of Southern California Medical Center is an American College of Surgeons verified Level I trauma center. After approval by the Institutional Review Board, all trauma patients receiving a PRBC transfusion over a 9-year period ending in December 2008 were identified using the Institutional Trauma Registry and Blood Bank Database. A massive transfusion was defined as a transfusion of 10 or more PRBC units during the initial 24 hours after admission. Patient variables abstracted included age, gender, mechanism of injury (blunt vs penetrating), blood pressure on admission, Glasgow Coma Scale (GCS), Injury Severity Score (ISS), Abbreviated Injury Score (AIS) for each body region (head, chest, abdomen, extremity), and outcome. Continuous variables were converted into dichotomous variables using clinically relevant cut-points (age ≥ 55 years, systolic blood pressure < 90 mmHg, GCS ≤ 8 , ISS ≥ 25 , AIS ≥ 3). The numbers of PRBCs, fresh frozen plasma (FFP), platelet, and cryoprecipitate units transfused at 12 hours, 24 hours, and at hospital discharge were abstracted from the blood bank database. During the study period, apheresis platelets (aPLT) containing $\geq 3 \times 10^{11}$ platelets per unit were used exclusively.

Patients were classified into 4 clinically relevant groups according to the aPLT:PRBC ratios received at 12 and 24 hours after admission: Low ratio ($< 1:18$), medium ratio ($\geq 1:18$ and $< 1:12$), high ratio ($\geq 1:12$ and $< 1:6$), and highest ratio ($\geq 1:6$). The primary outcomes measure tested was mortality at 12 and 24 hours as well as overall survival to discharge.

Statistical analysis

Differences in the demographic and clinical characteristics between the 4 platelet ratio groups were evaluated using analysis of variance.

Logistic regression was performed to control for confounders that were significantly different at the $p < 0.05$ level between the compared groups using chi-square test or Fisher's exact test. Adjusted odds ratio (OR) and 95% confidence intervals (CI) were calculated for each ratio group, with the highest ratio group (aPLT:PRBC $\geq 1:6$) set as the reference cohort (OR 1.0).

A Cox regression model was used to further evaluate the association between the aPLT:PRBC ratio and mortality, treating the aPLT:PRBC ratio as a time-dependent covariate. This analysis allowed examination of the relationship between in-hospital mortality and the aPLT:PRBC ratio over time, taking into account the fact that patients might have transitioned between the ratio groups at each time interval of interest (2-hour intervals from admission to 24 hours postadmission).

In addition, in order to determine if the aPLT:PRBC ratio was independently associated with mortality, a stepwise logistic regression model was performed including all factors that had a $p < 0.2$ from the univariate analysis.

Values are reported as means \pm standard deviation (SD) for continuous variables and as percentages for categorical variables. All analyses were performed using the Statistical Package for Social Sciences (SPSS Windows), version 12.0 (SPSS Inc).

RESULTS

During the 9-year study period, 5,872 (18.2%) of the 32,289 injured patients admitted to this center received a blood transfusion. A total of 657 (11.2%) of these patients required an MT. At 24 hours after admission, a total of 171 patients (26.0%) received a low ratio, 77 patients (11.7%) a medium ratio, 249 patients (37.9%) a high ratio, and 160 patients (24.4%) the highest ratio of aPLT:PRBC. No statistically significant change in the incidence of the different aPLT:PRBC ratios were observed over the 9-year study period. The platelet transfusion was front loaded, with 64.1% of all aPLT units transfused within the first 24 hours being given within the first 6 hours after admission. This was constant throughout all 4 groups, with 77.8%, 58.3%, 68.4%, and 59.9% of the aPLT units being given within the first 6 hours in the low, medium, high and highest ratio groups, respectively. The average age of these patients was 34.9 ± 17.0 years and the mean ISS was 28.7 ± 14.5 . Detailed demographic and clinical injury characteristics of the study groups are described in Table 1. Table 2 depicts the summary of blood components used for resuscitation during the initial 24 hours stratified by platelet ratio groups. These, along with the differences in demographic and clinical injury data, were corrected for in the logistic regression.

Table 1. Demographic and Clinical Injury Characteristics of All Massively Transfused Patients Stratified by Platelet Ratio

Characteristic	Total (n = 657)	Low ratio (n = 171)	Medium ratio (n = 77)	High ratio (n = 249)	Highest ratio (n = 160)	p Value
Age ≥ 55 y, % (n)	12.6 (83/657)	11.7 (20/171)	11.7 (9/77)	12.9 (32/249)	13.8 (22/160)	0.942
Male, % (n)	83.6 (549/657)	86.0 (147/171)	87.0 (67/77)	80.7 (201/249)	83.8 (134/160)	0.415
Penetrating, % (n)	54.8 (360/657)	53.8 (92/171)	58.4 (45/77)	55.4 (138/249)	53.1 (85/160)	0.873
SBP < 90 mmHg, % (n)	31.4 (199/633)	40.2 (66/164)	18.9 (14/74)	33.2 (80/241)	25.3 (39/154)	0.003
GCS ≤ 8 , % (n)	31.6 (205/649)	44.8 (74/165)	27.3 (21/77)	27.8 (69/248)	25.8 (41/159)	<0.001
ISS, mean \pm SD	28.7 \pm 14.5	29.9 \pm 16.1	27.3 \pm 12.6	28.7 \pm 14.6	28.1 \pm 13.3	0.545
ISS ≥ 25 , % (n)	64.4 (423/657)	64.3 (110/171)	62.3 (48/77)	65.1 (162/249)	64.4 (103/160)	0.979
Head AIS ≥ 3 , % (n)	21.5 (141/657)	21.1 (36/171)	22.1 (17/77)	18.5 (46/249)	26.3 (42/160)	0.317
Chest AIS ≥ 3 , % (n)	51.1 (336/657)	50.9 (87/171)	42.9 (33/77)	52.2 (130/249)	53.8 (86/160)	0.446
Abdomen AIS ≥ 3 , % (n)	63.0 (414/657)	62.0 (106/171)	59.7 (46/77)	68.3 (170/249)	57.5 (92/160)	0.140
Extremity AIS ≥ 3 , % (n)	36.5 (240/657)	37.4 (64/171)	40.3 (31/77)	34.9 (87/249)	36.3 (58/160)	0.850

AIS, Abbreviated Injury Score; GCS, Glasgow Coma Scale; ISS, Injury Severity Score; SBP, systolic blood pressure; SD, standard deviation.

Mortality was examined at 12 and 24 hours and is illustrated in Figures 1 and 2, respectively. At 12 hours, the overall mortality was 32.7% (n = 215). A stepwise increase in adjusted mortality with decreasing platelet ratio was observed at this time point. Using the highest ratio group as the reference group, the adjusted (adj.) relative risk of death was 1.77 (95% CI 0.99 to 3.17; adj. p = 0.054) for the high ratio group, 2.44 (95% CI 1.13 to 5.26; adj. p = 0.023) for the medium ratio group, and 3.75 (95% CI 1.88 to 7.45; adj. p < 0.001) for the low ratio group (Fig. 1). At 24 hours, the overall mortality was 36.7% (n = 241), increasing in a similar stepwise fashion with decreasing aPLT:PRBC ratio. The adjusted relative risk of death was 1.67 (95% CI 0.99 to 2.82; adj. p = 0.054) for the high ratio group, 2.28 (95% CI 1.19 to 4.39; adj. p = 0.013) for the medium ratio group, and 5.51 (95% CI 2.76 to 10.98; adj. p < 0.001) for the low ratio group (Fig. 2). For overall survival to discharge, as the platelet ratio increased, a stepwise decrease in mortality was seen, from 72.1% to 33.1% (adj. p < 0.001).

Subsequently, the Cox regression analysis was performed using the aPLT:PRBC ratio as a time-dependent covariate. A decreasing aPLT:PRBC ratio was significantly associated with increasing mortality (adj. p = 0.007, OR [95% CI] 1.87 [1.18 to 2.97], adjusted for FFP:PRBC ratio [%],

cryoprecipitate, hypotension on admission [<90 mmHg vs ≥ 90 mmHg], and GCS on admission [≤ 8 vs > 8]).

After univariate analysis, the risk factors associated with mortality at 24 hours were identified (Table 3). These factors were used in addition to the aPLT:PRBC ratio, the FFP:PRBC ratio, and the PRBC units transfused within 24 hours to build a stepwise logistic regression model to identify independent predictors of mortality at 24 hours. Variables independently associated with increased mortality included a GCS ≤ 8 , PRBC units transfused within 24 hours, hypotension on admission, and an ISS ≥ 25 . Variables independently associated with improved survival at 24 hours included the FFP:PRBC ratio and the aPLT:PRBC ratio. The R^2 for this regression model was 0.54 (Table 4).

DISCUSSION

For acutely injured patients surviving to hospital, the primary cause of preventable death is uncontrolled blood loss.²¹⁻²³ For these patients requiring an MT, defined in most research protocols as ≥ 10 units of PRBC within the first 6 to 24 hours, the aggressive early use of plasma has been widely applied as the central component of a damage control resuscitation strategy. Although not universally

Table 2. Blood Component Summary for the First 24 Hours Stratified by Platelet Ratio

Variable	Total (n = 657)	Low ratio (n = 171)	Medium ratio (n = 77)	High ratio (n = 249)	Highest ratio (n = 160)	p Value
PRBC, U, mean \pm SD	18.0 \pm 9.8	15.5 \pm 6.6	19.7 \pm 10.6	20.5 \pm 12.1	15.8 \pm 6.7	<0.001
FFP, U, mean \pm SD	8.6 \pm 7.3	5.1 \pm 5.5	9.4 \pm 9.0	10.3 \pm 8.1	9.2 \pm 5.3	<0.001
aPLT, U, mean \pm SD	1.9 \pm 1.7	0.2 \pm 0.4	1.3 \pm 0.8	2.4 \pm 1.5	3.4 \pm 1.5	<0.001
FFP:PRBC ratio, %, mean \pm SD*	48.2 \pm 31.7	34.0 \pm 37.0	46.2 \pm 26.7	51.0 \pm 26.8	60.1 \pm 29.2	<0.001
Cryoprecipitate, U, mean \pm SD	4.9 \pm 8.7	2.0 \pm 5.1	4.8 \pm 7.6	6.6 \pm 9.9	5.5 \pm 9.6	<0.001

*FFP:PRBC ratio (%) = (units FFP/units PRBC) \times 100.

aPLT, apheresis platelets; FFP, fresh frozen plasma; PRBC, packed red blood cells.




Figure 1. Mortality for massively transfused patients at 12 hours stratified by platelet ratio. Adjusted for GCS on admission (≤ 8 versus > 8), FFP:PRBC ratio (%) at 12 h, cryoprecipitate at 12 h. adj, adjusted; aPLT, apheresis platelets; FFP, fresh frozen plasma; GCS, Glasgow Coma Scale; PRBC, packed red blood cells.

supported,²⁴⁻²⁶ the bulk of the evidence from both military⁶⁻⁸ and civilian⁹⁻¹⁷ centers, including the recently published multicenter study by Holcomb and colleagues¹⁰ incorporating data from 16 civilian Level I trauma centers, demonstrates that a survival advantage is conferred by the aggressive use of plasma in ratios approaching 1:1.

For platelets, however, the evidence is less clear.^{10,13,18-20,27} One of the earliest attempts to quantitate the impact of platelets in MT was performed by Cinat and associates.¹⁹ Although limited by their definition of an MT (> 50 units in 48 hours), and the inclusion of whole blood and component red cells as well as pooled and apheresis platelets, they showed that survivors received a higher platelet ratio of 1:7.7 as compared with 1:11.9 for nonsurvivors. In a subsequent before-and-after study by Gunter and coauthors,²⁰ 63 patients undergoing MT who received platelets at a ratio of $\geq 1:5$ had a lower mortality than a comparison group receiving a ratio of $< 1:5$ (38% vs 61%, $p = 0.001$). Data extracted from 462 penetrating combat casualties treated in Baghdad demonstrated similar results.¹⁸ Stratified by platelet ratios, there was a stepwise increase in survival with increasing platelet transfusion from a low of 64% with a ratio of $< 1:16$ to upwards of 95% for ratios exceeding 1:8. The aPLT:PRBC ratio was independently associated with survival at both 24 hours and 30 days. Finally, in the multicenter study by Holcomb and associates,¹⁰ a practical approach to this question was taken by grouping patients according to both their plasma and platelet ratios. Patients receiving a combination of high plasma and




Figure 2. Mortality for massively transfused patients at 24 hours stratified by platelet ratio. Adjusted for hypotension on admission (< 90 mmHg versus ≥ 90 mmHg), GCS on admission (≤ 8 versus > 8), FFP:PRBC ratio (%) at 24 h, cryoprecipitate at 24 h. adj, adjusted; aPLT, apheresis platelets; FFP, fresh frozen plasma; GCS, Glasgow Coma Scale; PRBC, packed red blood cells.

high platelets had improved 6-hour, 24-hour, and 30-day survival.

In our study, increasing platelet transfusion, in ratios approaching 1:6, was associated with a stepwise improvement in survival at 12 and 24 hours and in overall survival to discharge. With each apheresis unit equivalent to approximately 6 random donor units, this represents an optimal ratio of 1:1 for random platelets:PRBC. The aPLT:PRBC ratio was also found to be independently associated with improved survival.

The role of platelets in the acute resuscitation of critically ill trauma patients has undergone change as our transfusion protocols have evolved. In the era of stored whole blood transfusion, one of the earliest defects seen after massive transfusion was a deficit in the functional platelet concentration.²⁸⁻³¹ When stored in whole blood at 4°C, these highly temperature-sensitive platelets rapidly became dysfunctional and were quickly cleared from the systemic circulation. Clotting factors, however, with the possible exception of factors V and VIII, were well retained in stored whole blood. With the North American red cell replacement standard changing to component therapy, these clotting factors also became depleted in patients requiring massive transfusions of factor-poor PRBC units. When comparing the impact of the platelet deficit with plasma, it appears that plasma exerts a stronger effect on mortality than platelets. In Hirshberg and coworkers,³² computer modeling simulation of massive transfusion, prolongation

Table 3. Risk Factors for Mortality at 24 Hours for Massively Transfused Patients

Variable	Mortality at 24 h, %	n	p Value	Odds ratio (95% CI)
Gender				
Male	37.3	205/549	0.430	1.19 (0.77–1.84)
Female	33.3	36/108		
Mechanism				
Penetrating	40.6	146/360	0.023	1.45 (1.05–2.00)
Blunt	32.0	95/297		
Age, y				
≥ 55	32.5	27/83	0.401	0.81 (0.50–1.32)
< 55	37.3	214/574		
SBP, mmHg				
< 90	55.3	110/199	<0.001	3.16 (2.23–4.48)
≥ 90	28.1	122/434		
GCS				
≥ 8	63.9	131/205	<0.001	5.72 (3.99–8.19)
> 8	23.6	105/444		
ISS				
≥ 25	43.5	184/423	<0.001	2.39 (1.68–3.41)
< 25	24.4	57/234		
AIS Head				
≥ 3	37.6	53/141	0.801	1.05 (0.72–1.54)
< 3	36.4	188/516		
AIS Chest				
≥ 3	41.4	139/336	0.011	1.52 (1.10–2.09)
< 3	31.8	102/321		
AIS Abdomen				
≥ 3	40.3	167/414	0.011	1.54 (1.10–2.16)
< 3	30.5	74/243		
AIS Extremity				
≥ 3	32.1	77/240	0.064	0.72 (0.52–1.02)
< 3	39.3	164/417		

AIS, Abbreviated Injury Score; GCS, Glasgow Coma Scale; ISS, Injury Severity Score; SBP, systolic blood pressure.

of the prothrombin time was demonstrated to be the primary defect seen, followed later by a platelet deficit. They suggested that the dilution of platelets is not only slower, but likely more variable as well, due to individual variation in consumption and endogenous recruitment. In our regression, the R^2 value for FFP:PRBC ratio was 0.269 compared with 0.035 for aPLT:PRBC. This would suggest that of the 2, the primary focus during the acute resuscitation phase should be on plasma replacement. In fact, in a randomized controlled trial by Reed and colleagues³³ evaluating pooled platelet transfusion at a ratio of 1:2 versus plasma in patients receiving ≥12 units of whole blood in 12 hours, the conclusion was that platelet administration

did not affect microvascular nonsurgical bleeding. This study, although small, using only whole blood and achieving only a ratio of 1:2, is important because it is the only prospective randomized data available and supports the primary importance of plasma in these patients who have microvascular nonsurgical bleeding.

This study is limited by its retrospective study design. The errors inherent in any trauma registry, in particular, with respect to blood component transfusion, have been highlighted in our previous studies.^{12,34} Attempts have been made to mitigate this by using transfusion data abstracted exclusively from the blood bank, where dispensing and use data is stringently regulated by the US Food and Drug Administration (FDA). These regulations mandate that all blood banks maintain comprehensive records for each unit dispensed, and it is hoped that this minimized the errors associated with this retrospective analysis.

In the evidence base addressing the impact on survival of component replacement for acute resuscitation, there has been inconsistency in the exclusion of early deaths. In the analysis by Snyder and associates,²⁴ the “survival bias” was examined as a potential confounding signal that may categorize patients who survived to receive plasma as patients who survived because they received plasma. This is of particular concern in the evaluation of treatment effects on populations with a high rate of early deaths and a significant delay to initiation of treatment. We analyzed our results with the exclusion of deaths in the emergency department as well as those at 24 hours; however, the conclusions remained the same. In addition, our analysis of the timing of platelet transfusion showed that they were heavily front loaded and that a consistent proportion of the total 24-hour platelet load was administered within the first 6 hours across all groups. Furthermore, the “survival bias” was addressed by using the aPLT:PRBC ratio as a time-dependent covariate in the regression model. These results demonstrated again that with decreasing aPLT:PRBC ratios, mortality significantly increased.

This study did not provide any insight into which patients would go on to require an MT and therefore benefit from aggressive platelet use. In the wider application of these results, defining the predictors of the need for an MT will remain a critical goal for future studies.

Data regarding platelet function was also not available for analysis. Renal failure, liver dysfunction, and the presence of antiplatelet agents could not be accurately determined. The negative impact of hypothermia and acidosis on platelet function likewise could not be quantified. Platelet function analyzer data was also not available throughout the duration of the study. Although plasma and cryoprecipitate data were accurately captured and adjusted for, the

Table 4. Predictors of Mortality at 24 Hours

Step	Variable	Adjusted odds ratio (95% CI)	Adjusted p value	R ²
1	FFP:PRBC ratio (%) at 24 h*	0.96 (0.95–0.97)	<0.001	0.269
2	GCS ≤ 8	6.57 (3.98–10.86)	<0.001	0.167
3	PRBC units within 24 h	1.06 (1.04–1.08)	<0.001	0.041
4	aPLT:PRBC ratio (%) at 24 h†	0.92 (0.89–0.95)	<0.001	0.035
5	SBP < 90 mmHg	2.42 (1.49–3.95)	<0.001	0.016
6	ISS ≥ 25	2.05 (1.27–3.32)	0.003	0.012

Regression included variables with $p < 0.2$ on univariate analysis. The FFP:PRBC ratio (%) at 24 h, the aPLT:PRBC ratio (%) at 24 h, and the PRBC units transfused within 24 h were forced into the regression model.

*FFP:PRBC ratio (%) = (units FFP/units PRBC) \times 100.

†aPLT:PRBC ratio (%) = (units aPLT/units PRBC) \times 100.

aPLT, apheresis platelets; FFP, fresh frozen plasma; GCS, Glasgow Coma Scale; ISS, Injury Severity Score; PRBC, packed red blood cells; SBP, systolic blood pressure.

procoagulant effects of agents such as factor VIIa could not be accurately abstracted. Consequently, clear data on the functional coagulation status of these patients and its temporal association with platelet transfusion could not be analyzed.

Despite these limitations, this is the largest study to date examining the impact of apheresis platelet transfusion in patients undergoing an MT. In this study, there was a stepwise improvement in survival with increasing platelet-to-PRBC ratios. The ratio of apheresis platelets to blood was independently associated with survival.

In conclusion, for injured patients requiring a massive transfusion, as the apheresis platelet-to-red cell ratio approached 1:6, a stepwise improvement in survival was seen. The magnitude of the impact exerted by platelets on survival was not as strong as that of plasma transfusion. However, further prospective evaluation of the optimal platelet ratio and trigger for transfusion in patients undergoing a massive transfusion is warranted.

Author Contributions

Study conception and design: Inaba, Demetriades, Rhee
Acquisition of data: Lustenberger, Shulman, Nelson, Talving
Analysis and interpretation of data: Inaba, Lustenberger, Rhee, Holcomb, Blackburne, Shulman, Nelson, Talving, Demetriades

Drafting of manuscript: Inaba, Lustenberger

Critical revision: Inaba, Lustenberger, Rhee, Holcomb, Blackburne, Shulman, Nelson, Talving, Demetriades

REFERENCES

- Holcomb JB. Damage control resuscitation. *J Trauma* 2007;62:S36–37.
- Hess JR, Holcomb JB, Hoyt DB. Damage control resuscitation: The need for specific blood products to treat the coagulopathy of trauma. *Transfusion* 2006;46:685–686.
- Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: Directly addressing the early coagulopathy of trauma. *J Trauma* 2007;62:307–310.
- Malone DL, Dunne J, Tracy JK, et al. Blood transfusion, independent of shock severity, is associated with worse outcome in trauma. *J Trauma* 2003;54:898–905; discussion 905–907.
- Ketchum L, Hess JR, Hiippala S. Indications for early fresh frozen plasma, cryoprecipitate, and platelet transfusion in trauma. *J Trauma* 2006;60:S51–58.
- Borgman MA, Spinella PC, Perkins JG, et al. The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. *J Trauma* 2007;63:805–813.
- Spinella PC, Perkins JG, Grathwohl KW, et al. Effect of plasma and red blood cell transfusions on survival in patients with combat related traumatic injuries. *J Trauma* 2008;64:S69–77; discussion S77–78.
- Niles SE, McLaughlin DF, Perkins JG, et al. Increased mortality associated with the early coagulopathy of trauma in combat casualties. *J Trauma* 2008;64:1459–1463; discussion 1463–1465.
- Duchesne JC, Hunt JP, Wahl G, et al. Review of current blood transfusion strategies in a mature level I trauma center: Were we wrong for the last 60 years? *J Trauma* 2008;65:272–276; discussion 276–278.
- Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. *Ann Surg* 2008;248:447–458.
- Sperry JL, Ochoa JB, Gunn SR, et al. An FFP:PRBC transfusion ratio $\geq 1:1.5$ is associated with a lower risk of mortality after massive transfusion. *J Trauma* 2008;65:986–993.
- Teixeira PG, Inaba K, Shulman I, et al. Impact of plasma transfusion in massively transfused trauma patients. *J Trauma* 2009;66:693–697.
- Zink KA, Sambasivan CN, Holcomb JB, et al. A high ratio of plasma and platelets to packed red blood cells in the first 6 hours of massive transfusion improves outcomes in a large multicenter study. *Am J Surg* 2009;197:565–570; discussion 570.
- Maegele M, Lefering R, Paffrath T, et al. Red-blood-cell to plasma ratios transfused during massive transfusion are associated with mortality in severe multiple injury: A retrospective analysis from the trauma registry of the deutsche gesellschaft fur unfallchirurgie. *Vox Sang* 2008;95:112–119.

15. Cotton BA, Gunter OL, Isbell J, et al. Damage control hematology: The impact of a trauma exsanguination protocol on survival and blood product utilization. *J Trauma* 2008;64:1177–1182; discussion 1182–1183.
16. Gonzalez EA, Moore FA, Holcomb JB, et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. *J Trauma* 2007;62:112–119.
17. Moore FA, Nelson T, McKinley BA, et al. Is there a role for aggressive use of fresh frozen plasma in massive transfusion of civilian trauma patients? *Am J Surg* 2008;196:948–958; discussion 958–960.
18. Perkins JG, Andrew CP, Spinella PC, et al. An evaluation of the impact of apheresis platelets used in the setting of massively transfused trauma patients. *J Trauma* 2009;66:S77–84; discussion S84–85.
19. Cinat ME, Wallace WC, Nastanski F, et al. Improved survival following massive transfusion in patients who have undergone trauma. *Arch Surg* 1999;134:964–968; discussion 968–970.
20. Gunter OL Jr, Au BK, Isbell JM, et al. Optimizing outcomes in damage control resuscitation: Identifying blood product ratios associated with improved survival. *J Trauma* 2008;65:527–534.
21. Sauaia A, Moore FA, Moore EE, et al. Epidemiology of trauma deaths: A reassessment. *J Trauma* 1995;38:185–193.
22. Gruen RL, Jurkovich GJ, McIntyre LK, et al. Patterns of errors contributing to trauma mortality: Lessons learned from 2,594 deaths. *Ann Surg* 2006;244:371–380.
23. Teixeira PG, Inaba K, Hadjizacharia P, et al. Preventable or potentially preventable mortality at a mature trauma center. *J Trauma* 2007;63:1338–1346; discussion 1346–1347.
24. Snyder CW, Weinberg JA, McGwin G Jr, et al. The relationship of blood product ratio to mortality: Survival benefit or survival bias? *J Trauma* 2009;66:358–362; discussion 362–364.
25. Scalea TM, Bochicchio KM, Lumpkins K, et al. Early aggressive use of fresh frozen plasma does not improve outcome in critically injured trauma patients. *Ann Surg* 2008;248:578–584.
26. Kashuk JL, Moore EE, Johnson JL, et al. Postinjury life threatening coagulopathy: Is 1:1 fresh frozen plasma:packed red blood cells the answer? *J Trauma* 2008;65:261–270; discussion 270–271.
27. Cosgriff N, Moore EE, Sauaia A, et al. Predicting life-threatening coagulopathy in the massively transfused trauma patient: Hypothermia and acidosis revisited. *J Trauma* 1997;42:857–861; discussion 861–862.
28. Lim RC, Jr, Olcott C 4th, Robinson AJ, Blaisdell FW. Platelet response and coagulation changes following massive blood replacement. *J Trauma* 1973;13:577–582.
29. Nolan TE, Gallup DG. Massive transfusion: A current review. *Obstet Gynecol Surv* 1991;46:289–295.
30. Counts RB, Haisch C, Simon TL, et al. Hemostasis in massively transfused trauma patients. *Ann Surg* 1979;190:91–99.
31. Miller RD, Robbins TO, Tong MJ, Barton SL. Coagulation defects associated with massive blood transfusions. *Ann Surg* 1971;174:794–801.
32. Hirshberg A, Dugas M, Banez EI, et al. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: A computer simulation. *J Trauma* 2003;54:454–463.
33. Reed RL 2nd, Ciavarella D, Heimbach DM, et al. Prophylactic platelet administration during massive transfusion. A prospective, randomized, double-blind clinical study. *Ann Surg* 1986;203:40–48.
34. Inaba K, Teixeira PG, Shulman I, et al. The impact of uncross-matched blood transfusion on the need for massive transfusion and mortality: Analysis of 5,166 uncross-matched units. *J Trauma* 2008;65:1222–1226.